Remove 2022 Remove Diabetes Remove Immunization
article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

Food and Drug Administration for a “reckless and arbitrary” decision to remove a widely prescribed Eli Lilly drug for combating diabetes and obesity from an official shortages list , STAT tells us. from 1967 until 2022. … A trade group representing large compounding pharmacies has sued the U.S.

article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

On November 17, 2022, the FDA approved Provention Bio’s Tzield (teplizumab) , making it the first and only treatment to delay the onset of type 1 diabetes (T1D). Tzield’s approval brings the opportunity to explore how the drug can advance diabetes education, treatment, and management. “We Equity in early-stage testing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

US FDA expands approval to GSK’s Arexvy for adults aged 50-59, at increased risk

Express Pharma

Adults with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, heart failure and diabetes (3) are at increased risk for severe consequences from an RSV infection compared to those without these conditions. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation or death.(4)

Vaccines 111
article thumbnail

Why Balancing Blood Sugar is Vital for Hashimoto’s Health

The Thyroid Pharmacist

A review paper published in 2010 that discussed the relationship between thyroid dysfunction and metabolic disorders, highlighted the fact that patients with diabetes were up to three times more likely to develop a thyroid disorder. (7). Hypoglycemia is an early risk factor for developing diabetes. Type 2 Diabetes.

article thumbnail

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

PharmaShots

Was ranked the highest among the list of companies developing Cell & Gene therapy, followed by Novartis with a revenue of $50.54B and Spark Therapeutics with a revenue of $49.27B PharmaShots brings an informative report on the Top 20 Cell and Gene Therapy Companies based on the total Revenue generated in the year 2022 Total Revenue: $0.5M

article thumbnail

Advancing microbiome innovation

European Pharmaceutical Review

The recent FDA approvals of two microbiome products in the US, in November 2022 and April 2023, 1-2 represent a significant milestone, maturing the industry and paving the way for advancement and regulatory clearance of additional microbiome products in broader indications. Notably, from one donor to another, significant variations exist.

article thumbnail

Is Stevia Good or Bad for Hashimoto’s Disease?

The Thyroid Pharmacist

I knew he was right — sugar can contribute to a yeast overgrowth, lowered immunity, blood sugar issues, weight gain, diabetes, and a whole host of health problems (1-3) — but I was a sugar addict, and it was devastating to think that I would have to let go of this old friend and not have any sweetness in my life.